PG 22000

Drug Profile

PG 22000

Alternative Names: PG 2-2000

Latest Information Update: 10 Jan 2008

Price : $50

At a glance

  • Originator Pharmagenesis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Haematological disorders

Most Recent Events

  • 02 Nov 2005 No development reported - Preclinical for Haematological disorders in USA (unspecified route)
  • 08 Nov 2001 Preclinical development for Haematological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top